Episode

This Company Wants To Keep Your Heart Healthy – Meet Todd Usen CEO Adagio Medical – ADGM

Podcast
Smart Money Circle
Published
May 6, 2026
Duration seconds
1809
Processing state
not_requested
Canonical source
https://podcasters.spotify.com/pod/show/smartmoneycircle/episodes/This-Company-Wants-To-Keep-Your-Heart-Healthy--Meet-Todd-Usen-CEO-Adagio-Medical--ADGM-e3j0alf
Audio
https://anchor.fm/s/eb41dac/podcast/play/119597167/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-6%2F423625901-44100-2-59cadafef1e77.mp3
JSON
/v1/public/podcasts/smart-money-circle-95624/episodes/this-company-wants-to-keep-your-heart-healthy-meet-todd-usen-ceo-adagio-medical-adgm
Markdown
/podcast/smart-money-circle-95624/this-company-wants-to-keep-your-heart-healthy-meet-todd-usen-ceo-adagio-medical-adgm.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/smart-money-circle-95624/episodes/this-company-wants-to-keep-your-heart-healthy-meet-todd-usen-ceo-adagio-medical-adgm/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/smart-money-circle-95624/this-company-wants-to-keep-your-heart-healthy-meet-todd-usen-ceo-adagio-medical-adgm.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

This Company Wants To Keep Your Heart Healthy – Meet Todd Usen CEO Adagio Medical – ADGM Guest Todd Usen, Chief Executive Officer Adagio Medical Company: Adagio Medical Ticker: ADGM Website: https://adagiomedical.com/ Bio: Adagio Medical is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Ablation (ULTA) technology. ULTA is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The Company is currently focused on the treatment of ventricular tachycardia (VT) with its purpose-built vCLAS™ catheter, which is CE Marked and is currently under evaluation in the FULCRUM-VT U.S. IDE Pivotal Study. FULCRUM-VT, which took only eleven months to fully enroll 209 patients, completed enrollment in October 2025 and FDA approval of vCLAS is expected by the end of 2026.